Andrew Cittadine

At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 800 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.

Serra Ventures is a venture capital firm investing in early stage technology companies in markets throughout the U.S. Serra has invested in over 100 companies.

At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 800 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.

At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 800 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.

Avivo BioOptics’ (ABO) is optimizing the cancer screening process with its InPoint™ System – the first 10min, POC, CLIA-waived, early-stage cancer risk assessment – improving testing compliance and enhancing clinical outcomes by conveniently monitoring average risk patients annually to identify high-risk patients needing follow-on stardard-of-care. The first application for use is Colorectal cancer (CRC). The InPoint™ System assesses a patient’s risk of developing cancer. InPoint's underlying Low-coherence Enhanced Backscatter (LEBS) technology is an optical platform that examines and analyzes nanoscopic structural tissue changes. The technology is based on the concept of field carcinogenesis – during the initial stages of cancer, tissue changes spread throughout the organ due to common environmental insult and genetic composition. These changes are identified by the backscatter of light from the tissue. The first application for CRC screening identifies advanced adenomas (AA) in colorectal mucosa, from which ~90% of CRC originates. The InPoint™ System measures changes at a specific area (distal rectum) that are indicative of the entire organ examined (colon).